A practical reference on TB-500: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-20 and is reviewed periodically as new material appears.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
| Property | Value | Notes |
|---|---|---|
| Water content | Low in freshly lyophilised material | Rises after repeated opening of the same vial |
| Solution stability | Lower than powder stability | Frozen aliquots are preferred over repeated thawing |
| Purity assessment | Reversed-phase HPLC with UV detection | Peak-area percentage excludes salts and water |
| Salt form | Often the trifluoroacetate salt | Retained from acidic purification gradients |
| Light sensitivity | Not strongly photoreactive | Dark storage still advised for long-term keeping |
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
== History == In 1942, James Hamilton observed that prepubertal castration prevents the later development of male pattern baldness in mature men. In 1974, Julianne Imperato-McGinley of Cornell Medical College in New York attended a conference on birth defects. She reported on a group of intersex children in the Caribbean who appeared sexually ambiguous at birth, and were initially raised as girls, but then grew external male genitalia and other masculine characteristic after onset of puberty. These children, despite being raised as girls until puberty, were generally heterosexual and were termed "Guevedoces" by their local community, which means "penis at twelve" in Spanish. Her research group found these children shared a genetic mutation, causing deficiency of the 5α-reductase enzyme and male hormone dihydrotestosterone (DHT), which was found to have been the etiology behind abnormalities in male sexual development. Upon maturation, these individuals were observed to have smaller prostates which were underdeveloped, and were also observed to lack incidence of male pattern baldness. In 1975, copies of Imperato-McGinley's presentation were seen by P. Roy Vagelos, who was then serving as Merck's basic research chief. He was intrigued by the notion that decreased levels of DHT led to the development of smaller prostates. Dr. Vagelos then sought to create a drug that could mimic the condition found in these children to treat older men who had benign prostatic hyperplasia. Finasteride was developed by Merck under the code name MK-906.
=== Clinical relevance of sulcular epithelium in periodontal surgery === It was historically practised that the sulcular epithelium was removed during periodontal surgery. It was thought that the diseased ‘pocket epithelium’ could prevent re-attachment of healthy connective tissue and new periodontal ligament to the root surface. Furthermore, the ‘pocket epithelium’ which includes the sulcular epithelium was considered as a pathologic tissue lining containing bacteria and inflammatory cells which could result in periodontal destruction. Nonetheless, a study has demonstrated that its removal during flap surgery did not worsen attachment gain, pocket reduction or the healing outcome. In fact, its removal could lead to gingiva recession, a poorer esthetic outcome and increased root sensitivity or caries risk. Hence, it was concluded that the sulcular epithelium plays a protective role and shouldn’t be routinely removed unlike older periodontal techniques which necessitate it.
=== Formation from other heterocycles === Imidazole can be synthesized by the photolysis of 1-vinyltetrazole. This reaction will give substantial yields only if the 1-vinyltetrazole is made efficiently from an organotin compound, such as 2-tributylstannyltetrazole. The reaction, shown below, produces imidazole when R1 = R2 = R3 = hydrogen.
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}\varphi :\ &\rho \left({\partial _{t}u_{\varphi }}+u_{r}{\partial _{r}u_{\varphi }}+{\frac {u_{\varphi }}{r\sin \theta }}{\partial _{\varphi }u_{\varphi }}+{\frac {u_{\theta }}{r}}{\partial _{\theta }u_{\varphi }}+{\frac {u_{r}u_{\varphi }+u_{\varphi }u_{\theta }\cot \theta }{r}}\right)\\&\quad =-{\frac {1}{r\sin \theta }}{\partial _{\varphi }p}\\&\qquad +\mu \left({\frac {1}{r^{2}}}\partial _{r}\left(r^{2}{\partial _{r}u_{\varphi }}\right)+{\frac {1}{r^{2}\sin ^{2}\theta }}{\partial _{\varphi }^{2}u_{\varphi }}+{\frac {1}{r^{2}\sin \theta }}\partial _{\theta }\left(\sin \theta {\partial _{\theta }u_{\varphi }}\right)+{\frac {2\sin \theta {\partial _{\varphi }u_{r}}+2\cos \theta {\partial _{\varphi }u_{\theta }}-u_{\varphi }}{r^{2}\sin ^{2}\theta }}\right)\\&\qquad +{\frac {1}{3}}\mu {\frac {1}{r\sin \theta }}\partial _{\varphi }\left({\frac {1}{r^{2}}}\partial _{r}\left(r^{2}u_{r}\right)+{\frac {1}{r\sin \theta }}\partial _{\theta }\left(u_{\theta }\sin \theta \right)+{\frac {1}{r\sin \theta }}{\partial _{\varphi }u_{\varphi }}\right)\\&\qquad +\rho g_{\varphi }\\[8px]\end{aligned}}}
== Further reading == Feng Z.C.; Tsu R., eds. (1994). Porous Silicon. Singapore: World Scientific. ISBN 978-981-02-1634-4. Kovalev D.; Timoshenko V. Y.; Künzner N.; Gross E.; Koch F. (August 2001). "Strong explosive interaction of hydrogenated porous silicon with oxygen at cryogenic temperatures". Phys. Rev. Lett. 87 (6) 068301. Bibcode:2001PhRvL..87f8301K. doi:10.1103/PhysRevLett.87.068301. PMID 11497868.
=== Differential diagnosis === Hyperinsulinemia is often mistaken for diabetes or hypoglycaemia. These are separate, albeit related, conditions. Adipocytes will generate triglycerides in the presence of insulin but refers to a liver condition rather than a pancreatic one.
Noted for his longevity in the game, Fletcher played a total of 400 senior VFL/AFL games, which stands as the fifth-highest number of games by any player as of 2023. His AFL career length of 22 years and 58 days is an all-time league record (edging out Vic Cumberland, whose former record was five days shy of 22 years). Fletcher played his 400th game in Round 9, 2015, becoming the third player in VFL/AFL history to reach the milestone (after Michael Tuck and Kevin Bartlett); it would end up being his final game, as he was unable to recover from a groin injury sustained during the match. He holds the outright Essendon games record, having overtaken the previous record of 378 games held by Simon Madden in Round 1, 2014. He is the second-oldest player to play a VFL/AFL game, aged 40 years and 23 days at the time of his final game, behind only the aforementioned Vic Cumberland (who played the 1920 season at the age of 43). With his father, Ken, the Fletchers hold the record for the most VFL/AFL career games played by a father and son, with 664 games between them. On 12 January 2016, during the summer after his retirement, Fletcher was named as one of 34 past and present Essendon players found guilty over their use of illegal supplements during the 2012 AFL season. As a result, Fletcher was suspended from playing at all levels for 24 months, which with backdating and provisional suspension served resulted in suspension until November 2016. However, Fletcher had already retired the previous year, so the suspension was moot.
Sources: en.wikipedia.org
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.
Mass spectrometry confirms identity, because the measured mass is compared with the value expected from the sequence. Chromatography mainly reports how much of the material elutes as the target peak.
It usually describes the share of the chromatographic peak area recorded at a set wavelength. Salts, residual water, and solvent are excluded from that number, so it is not the same as mass fraction.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.